Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation

Circulation: Arrhythmia and Electrophysiology

Volumn 8, Issue 5, 2015, Pages 1057-1064

  Briceno, David F ^a   Villablanca, Pedro ^a   Cyrille, Nicole ^a   Massera, Daniele ^a   Bader, Eric ^a   Manheimer, Eric ^a   Aagaard, Philip ^a   Ferrick, Kevin ^a   Gross, Jay ^a   Kim, Soo Gyum ^a   Krumerman, Andrew ^a   Palma, Eugen ^a   Guttenplan, Nils ^a   Romero, Jorge ^a   Fisher, John ^a   Garcia, Mario ^a   Natale, Andrea ^{b,c,d,e,f,g,h}   Di Biase, Luigi ^b,c,i  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Texas Cardiac Arrhythmia Institute at St David's Medical Center   (United States)

^c The University of Texas at Austin   (United States)

^d STANFORD UNIVERSITY   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f SCRIPPS CLINIC   (United States)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF FOGGIA   (Italy)

Author keywords

anticoagulants; atrial appendage; atrial fibrillation; stroke; warfarin

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

ARTERIOVENOUS FISTULA; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; DEVICE EMBOLIZATION; HEART PERFORATION; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MEDLINE; META ANALYSIS; MORTALITY; PATIENT SAFETY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; COMPLICATION; HEART ATRIUM APPENDAGE; ORAL DRUG ADMINISTRATION; SEPTAL OCCLUDER; STROKE; SURGERY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPTAL OCCLUDER DEVICE; STROKE; WARFARIN;

EID: 84944676429     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.115.002993     Document Type: Article

References (25)

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Thou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-e267. doi: 10.1161/CIR.0000000000000041.
2. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-1046. doi: 10.1161/01. CIR.0000140263.20897.42.
3. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436-1450. doi: 10.1161/CIRCULATIONAHA.110.004424.
4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a metaanalysis of randomised trials. Lancet. 2014;383:955-962. doi: 10.1016/S0140-6736(13)62343-0.
5. Bayard YL, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E, Ramondo A, Ruzyllo W, Budts W, Montalescot G, Brugada P, Serruys PW, Vahanian A, Piéchaud JF, Bartorelli A, Marco J, Probst P, Kuck KH, Ostermayer SH, Büscheck F, Fischer E, Leetz M, Sievert H. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. EuroIntervention. 2010;6:220-226. doi: 10.4244/.
6. Bartus K, Han FT, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, Bartus S, Yakubov SJ, Lee RJ. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol. 2013;62:108-118. doi: 10.1016/j. jacc.2012.06.046.
7. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374:534-542. doi: 10.1016/S0140-6736(09)61343-X.
8. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1-12. doi: 10.1016/j.jacc.2014.04.029.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151. doi: 10.1056/NEJMoa0905561.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891. doe: 10.1056/NEJMoa1009638.
11. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi: 10.1056/NEJMoa1107039.
12. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, ͈pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104. doi: 10.1056/NEJMoa1310907.
13. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-. Circ J. 2012;76:2104-2111.
14. Kar S, Doshi S, Holmes DR Jr, Mobius-Winkler S, Reddy V, Schuler G, Sick P, Sievert H. Watchman left atrial appendage closure in atrial fibrillation patients 75 years or greater; A sub-analysis of the PROTECT AF Study. J Am Coll Cardiol. 2012;60:B26.
15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-W94.
16. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105-114. doi: 10.1016/j.cct.2006.04.004.
17. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.cochrane-handbook.org. Accessed February 21, 2015.
18. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
20. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
22. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
23. Lega JC, Bertoletti L, Gremillet C, Chapelle C, Mismetti P, Cucherat M, Vital-Durand D, Laporte S; Meta-Embol Group. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation. PLoS One. 2014;9:e91398. doi: 10.1371/journal.pone.0091398.
24. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-2391. doi: 10.1161/CIRCULATIONAHA.112.115410.
25. Bajaj NS, Parashar A, Agarwal S, Sodhi N, Poddar KL, Garg A, Tuzcu EM, Kapadia SR. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. JACC Cardiovasc Interv. 2014;7:296-304. doi: 10.1016/j.jcin.2013.11.010.